Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ocular Therapeutix, Inc (OCUL) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ocular Therapeutix, Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1393434.
Total stock buying since 2014: $26,252,040.
Total stock sales since 2014: $74,794,715.
Total stock option exercises since 2014: $1,084,858.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 10,000 | $69,600 | 120,319 | $1,026,612 | 0 | $0 |
| 2024 | 930,851 | $6,999,999 | 163,603 | $1,033,519 | 30,302 | $266,657 |
| 2023 | 1,544,961 | $5,024,763 | 45,403 | $193,079 | 0 | $0 |
| 2022 | 350,000 | $1,753,444 | 0 | $0 | 9,469 | $11,552 |
| 2021 | 150,900 | $976,275 | 10,000 | $143,000 | 0 | $0 |
| 2020 | 1,829,073 | $8,707,023 | 25,000 | $0 | 25,000 | $150,500 |
| 2019 | 339,689 | $1,134,314 | 0 | $0 | 0 | $0 |
| 2018 | 86,800 | $514,136 | 0 | $0 | 0 | $0 |
| 2017 | 69,500 | $304,781 | 0 | $0 | 189,393 | $494,315 |
| 2016 | 55,300 | $422,605 | 0 | $0 | 58,357 | $78,781 |
| 2015 | 25,000 | $332,100 | 3,122,470 | $72,398,505 | 76,111 | $83,053 |
| 2014 | 1,000 | $13,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 1,066 | $13,250 | 0 | $0 |
| 2025-08 | 0 | $0 | 29,453 | $354,612 | 0 | $0 |
| 2025-06 | 0 | $0 | 13,861 | $111,581 | 0 | $0 |
| 2025-05 | 10,000 | $69,600 | 29,079 | $208,737 | 0 | $0 |
| 2025-02 | 0 | $0 | 40,559 | $289,033 | 0 | $0 |
| 2025-01 | 0 | $0 | 6,301 | $49,399 | 0 | $0 |
| 2024-11 | 0 | $0 | 28,339 | $255,314 | 0 | $0 |
| 2024-08 | 0 | $0 | 22,712 | $204,861 | 0 | $0 |
| 2024-05 | 0 | $0 | 23,900 | $138,494 | 0 | $0 |
| 2024-02 | 930,851 | $6,999,999 | 44,139 | $214,513 | 30,302 | $266,657 |
| 2024-01 | 0 | $0 | 44,513 | $220,337 | 0 | $0 |
| 2023-12 | 1,538,461 | $4,999,998 | 0 | $0 | 0 | $0 |
| 2023-08 | 6,500 | $24,765 | 0 | $0 | 0 | $0 |
| 2023-07 | 0 | $0 | 832 | $4,101 | 0 | $0 |
| 2023-02 | 0 | $0 | 44,571 | $188,978 | 0 | $0 |
| 2022-10 | 20,000 | $78,970 | 0 | $0 | 0 | $0 |
| 2022-09 | 150,000 | $689,179 | 0 | $0 | 0 | $0 |
| 2022-05 | 0 | $0 | 0 | $0 | 9,469 | $11,552 |
| 2022-02 | 50,000 | $247,950 | 0 | $0 | 0 | $0 |
| 2022-01 | 130,000 | $737,345 | 0 | $0 | 0 | $0 |
| 2021-12 | 145,900 | $926,825 | 0 | $0 | 0 | $0 |
| 2021-08 | 5,000 | $49,450 | 0 | $0 | 0 | $0 |
| 2021-05 | 0 | $0 | 10,000 | $143,000 | 0 | $0 |
| 2020-12 | 0 | $0 | 25,000 | $0 | 25,000 | $150,500 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Notman Donald (See Remarks) | Sale | 1,066 | 12.43 | 13,250 |
| 2025-08-25 | Nayak Sanjay (Chief Strategy Officer) | Sale | 1,885 | 12.04 | 22,695 |
| 2025-08-25 | Kaiser Peter (Chief Development Officer) | Sale | 3,011 | 12.04 | 36,252 |
| 2025-08-25 | Dugel Pravin (See Remarks) | Sale | 21,494 | 12.04 | 258,787 |
| 2025-08-25 | Heier Jeffrey S. (Chief Scientific Officer) | Sale | 3,063 | 12.04 | 36,878 |
| 2025-06-02 | Waheed Nadia (Chief Medical Officer) | Sale | 13,861 | 8.05 | 111,581 |
| 2025-05-23 | Nayak Sanjay (Chief Strategy Officer) | Sale | 1,862 | 7.17 | 13,350 |
| 2025-05-23 | Kaiser Peter (Chief Development Officer) | Sale | 2,974 | 7.17 | 21,323 |
| 2025-05-23 | Dugel Pravin (See Remarks) | Sale | 21,219 | 7.18 | 152,352 |
| 2025-05-23 | Heier Jeffrey S. (Chief Scientific Officer) | Sale | 3,024 | 7.18 | 21,712 |
| 2025-05-08 | Lindstrom Richard L Md | Buy | 10,000 | 6.96 | 69,600 |
| 2025-02-24 | Nayak Sanjay (Chief Strategy Officer) | Sale | 1,895 | 6.84 | 12,961 |
| 2025-02-24 | Kaiser Peter (Chief Development Officer) | Sale | 3,009 | 6.87 | 20,671 |
| 2025-02-24 | Dugel Pravin (See Remarks) | Sale | 21,475 | 6.87 | 147,533 |
| 2025-02-24 | Heier Jeffrey S. (Chief Scientific Officer) | Sale | 3,061 | 6.87 | 21,029 |
| 2025-02-04 | Notman Donald (See Remarks) | Sale | 11,119 | 7.81 | 86,839 |
| 2025-01-31 | Notman Donald (See Remarks) | Sale | 6,301 | 7.84 | 49,399 |
| 2024-11-25 | Nayak Sanjay (Chief Strategy Officer) | Sale | 1,814 | 9.00 | 16,326 |
| 2024-11-25 | Kaiser Peter (Chief Development Officer) | Sale | 2,897 | 9.01 | 26,101 |
| 2024-11-25 | Dugel Pravin (See Remarks) | Sale | 20,680 | 9.01 | 186,326 |
| 2024-11-25 | Heier Jeffrey S. (Chief Scientific Officer) | Sale | 2,948 | 9.01 | 26,561 |
| 2024-08-23 | Nayak Sanjay (Chief Strategy Officer) | Sale | 1,832 | 9.02 | 16,524 |
| 2024-08-23 | Dugel Pravin (See Remarks) | Sale | 20,880 | 9.02 | 188,337 |
| 2024-05-23 | Nayak Sanjay (Chief Strategy Officer) | Sale | 2,274 | 5.84 | 13,280 |
| 2024-05-23 | Dugel Pravin (See Remarks) | Sale | 21,626 | 5.79 | 125,214 |
| 2024-02-27 | Lindstrom Richard L Md | Option Ex | 30,302 | 8.80 | 266,657 |
| 2024-02-26 | Summer Road Llc | Buy | 930,851 | 7.52 | 6,999,999 |
| 2024-02-05 | Strassburger Philip C. (General Counsel) | Sale | 6,029 | 4.86 | 29,300 |
| 2024-02-05 | Ozden Rabia Gurses (Chief Medical Officer) | Sale | 6,346 | 4.86 | 30,841 |
| 2024-02-05 | Notman Donald (Chief Financial Officer) | Sale | 6,212 | 4.86 | 30,190 |
| 2024-02-05 | Mattessich Antony C. (President and CEO) | Sale | 19,642 | 4.86 | 95,460 |
| 2024-02-05 | White Christopher G (Chief Business Officer) | Sale | 5,910 | 4.86 | 28,722 |
| 2024-01-31 | Strassburger Philip C. (General Counsel) | Sale | 6,831 | 4.95 | 33,813 |
| 2024-01-31 | Ozden Rabia Gurses (Chief Medical Officer) | Sale | 7,764 | 4.95 | 38,431 |
| 2024-01-31 | Notman Donald (Chief Financial Officer) | Sale | 6,433 | 4.95 | 31,843 |
| 2024-01-31 | Mattessich Antony C. (President and CEO) | Sale | 18,338 | 4.95 | 90,773 |
| 2024-01-31 | White Christopher G (Chief Business Officer) | Sale | 5,147 | 4.95 | 25,477 |
| 2023-12-14 | Summer Road Llc | Buy | 1,538,461 | 3.25 | 4,999,998 |
| 2023-08-30 | Mattessich Antony C. (President and CEO) | Buy | 6,500 | 3.81 | 24,765 |
| 2023-07-07 | Ozden Rabia Gurses (Chief Medical Officer) | Sale | 832 | 4.93 | 4,101 |
| 2023-02-06 | Strassburger Philip C. (General Counsel) | Sale | 6,181 | 4.24 | 26,207 |
| 2023-02-06 | Ozden Rabia Gurses (Chief Medical Officer) | Sale | 6,416 | 4.24 | 27,203 |
| 2023-02-06 | Notman Donald (Chief Financial Officer) | Sale | 6,476 | 4.24 | 27,458 |
| 2023-02-06 | Mattessich Antony C. (President and CEO) | Sale | 19,669 | 4.24 | 83,396 |
| 2023-02-06 | White Christopher G (Chief Business Officer) | Sale | 5,829 | 4.24 | 24,714 |
| 2022-10-11 | Summer Road Llc | Buy | 10,000 | 3.90 | 38,990 |
| 2022-10-10 | Summer Road Llc | Buy | 10,000 | 4.00 | 39,980 |
| 2022-09-29 | Summer Road Llc | Buy | 18,800 | 4.04 | 75,989 |
| 2022-09-28 | Summer Road Llc | Buy | 1,200 | 4.10 | 4,920 |
| 2022-09-27 | Summer Road Llc | Buy | 130,000 | 4.68 | 608,270 |
| 2022-05-12 | Lindstrom Richard L Md | Option Ex | 9,469 | 1.22 | 11,552 |
| 2022-02-23 | Summer Road Llc | Buy | 10,000 | 4.80 | 47,990 |
| 2022-02-18 | Summer Road Llc | Buy | 40,000 | 5.00 | 199,960 |
| 2022-01-28 | Summer Road Llc | Buy | 4,023 | 5.20 | 20,919 |
| 2022-01-27 | Summer Road Llc | Buy | 1,477 | 5.20 | 7,680 |
| 2022-01-24 | Summer Road Llc | Buy | 44,400 | 5.31 | 235,897 |
| 2022-01-21 | Summer Road Llc | Buy | 12,152 | 5.56 | 67,528 |
| 2022-01-20 | Summer Road Llc | Buy | 17,948 | 5.71 | 102,393 |
| 2022-01-18 | Summer Road Llc | Buy | 6,807 | 6.00 | 40,828 |
| 2022-01-14 | Summer Road Llc | Buy | 33,193 | 6.03 | 200,120 |
| 2022-01-13 | Summer Road Llc | Buy | 10,000 | 6.20 | 61,980 |
| 2021-12-15 | Summer Road Llc | Buy | 15,000 | 6.22 | 93,240 |
| 2021-12-14 | Summer Road Llc | Buy | 29,490 | 6.42 | 189,178 |
| 2021-12-13 | Summer Road Llc | Buy | 10,510 | 6.50 | 68,304 |
| 2021-12-10 | Summer Road Llc | Buy | 30,000 | 6.65 | 199,500 |
| 2021-12-08 | Summer Road Llc | Buy | 5,300 | 6.75 | 35,775 |
| 2021-12-06 | Summer Road Llc | Buy | 55,600 | 6.13 | 340,828 |
| 2021-08-20 | Mattessich Antony C. (President and CEO) | Buy | 5,000 | 9.89 | 49,450 |
| 2021-05-20 | Lindstrom Richard L Md | Sale | 10,000 | 14.30 | 143,000 |
| 2020-12-03 | Peacock Bruce | Sale | 25,000 | .00 | 0 |
| 2020-12-03 | Peacock Bruce | Option Ex | 25,000 | 6.02 | 150,500 |
| 2020-10-16 | Summer Road Llc | Buy | 437 | 10.48 | 4,579 |
| 2020-05-19 | Summer Road Llc | Buy | 363,636 | 5.50 | 1,999,998 |
| 2020-03-24 | Summer Road Llc | Buy | 35,052 | 4.87 | 170,703 |
| 2020-03-23 | Summer Road Llc | Buy | 64,948 | 4.66 | 302,397 |
| 2020-03-20 | Summer Road Llc | Buy | 9,100 | 4.52 | 41,122 |
| 2020-03-19 | Summer Road Llc | Buy | 40,900 | 4.63 | 189,244 |
| 2020-03-18 | Summer Road Llc | Buy | 344,938 | 4.62 | 1,594,303 |
| 2020-03-17 | Summer Road Llc | Buy | 550,000 | 4.66 | 2,563,000 |
| 2020-03-16 | Summer Road Llc | Buy | 194,262 | 4.16 | 807,158 |
| 2020-03-13 | Summer Road Llc | Buy | 210,800 | 4.63 | 976,004 |
| 2020-01-02 | Opaleye Management Inc. | Buy | 15,000 | 3.90 | 58,515 |
| 2019-12-30 | Opaleye Management Inc. | Buy | 20,000 | 3.97 | 79,420 |
| 2019-06-14 | Williams Leslie J. (Director) | Buy | 4,500 | 4.40 | 19,800 |
| 2019-06-14 | Notman Donald (Chief Financial Officer) | Buy | 2,500 | 4.33 | 10,825 |
| 2019-06-07 | Sawhney Amarpreet (Chairman of the Board) | Buy | 65,468 | 3.02 | 197,713 |
| 2019-06-06 | Mattessich Antony C. (President & CEO) | Buy | 40,000 | 2.81 | 112,400 |
| 2019-06-06 | Sawhney Amarpreet (Chairman of the Board) | Buy | 59,000 | 2.80 | 165,200 |
| 2019-06-05 | Sawhney Amarpreet (Chairman of the Board) | Buy | 32,852 | 2.91 | 95,599 |
| 2019-06-04 | Sawhney Amarpreet (Chairman of the Board) | Buy | 12,928 | 2.92 | 37,749 |
| 2019-05-28 | Goldstein Michael H. (Chief Medical Officer) | Buy | 12,000 | 2.51 | 30,119 |
| 2019-03-15 | Goldstein Michael H. (Chief Medical Officer) | Buy | 10,000 | 4.15 | 41,500 |
| 2019-03-15 | Heier Jeffrey S. (Director) | Buy | 24,000 | 4.15 | 99,600 |
| 2019-03-13 | Lindstrom Richard L Md (Director) | Buy | 56,441 | 4.33 | 244,389 |
| 2018-12-14 | Hanley Kevin F. (See Remarks) | Buy | 10,000 | 5.50 | 55,000 |
| 2018-12-10 | Hanley Kevin F. (SEE REMARKS) | Buy | 10,000 | 5.60 | 56,000 |
| 2018-12-06 | Bollag Daniel M (See Remarks) | Buy | 17,400 | 5.76 | 100,224 |
| 2018-08-20 | Mattessich Antony C. (President & CEO) | Buy | 20,000 | 5.95 | 119,000 |
| 2018-08-14 | Notman Donald (Chief Financial Officer) | Buy | 12,500 | 6.29 | 78,625 |
| 2018-08-10 | Mattessich Antony C. (President and CEO) | Buy | 16,900 | 6.23 | 105,287 |
| 2017-12-21 | Sawhney Amarpreet (Exec Chairman of the Board) | Option Ex | 189,393 | 2.61 | 494,315 |
| 2017-12-12 | Mattessich Antony C. (President and C.E.O.) | Buy | 21,000 | 4.29 | 90,090 |
| 2017-12-07 | Notman Donald (Chief Financial Officer) | Buy | 4,800 | 4.00 | 19,200 |
| 2017-12-06 | Bollag Daniel M (See Remarks) | Buy | 24,700 | 3.93 | 97,071 |
| 2017-11-16 | Sawhney Amarpreet (Exec. Chairman of the Board) | Buy | 19,000 | 5.18 | 98,420 |
| 2016-12-15 | Sawhney Amarpreet (President and CEO) | Buy | 45,300 | 7.85 | 355,605 |
| 2016-08-05 | Sawhney Amarpreet (President and CEO) | Option Ex | 58,357 | 1.35 | 78,781 |
| 2016-06-09 | Sawhney Amarpreet (President and CEO) | Buy | 10,000 | 6.70 | 67,000 |
| 2015-11-17 | Sawhney Amarpreet (President and CEO) | Buy | 10,000 | 8.25 | 82,500 |
| 2015-09-15 | Fortune James (Chief Operating Officer) | Sale | 9,470 | 17.16 | 162,505 |
| 2015-09-14 | Sawhney Amarpreet (President and CEO) | Buy | 15,000 | 16.64 | 249,600 |
| 2015-06-15 | Versant Side Fund Iii, L.p. (10% Owner) | Sale | 320,000 | 22.00 | 7,040,000 |
| 2015-06-15 | Warden Charles M (Director) | Sale | 320,000 | 22.00 | 7,040,000 |
| 2015-06-10 | Versant Side Fund Iii, L.p. (10% Owner) | Sale | 427,000 | 22.00 | 9,394,000 |
| 2015-06-10 | Sv Life Sciences Fund Iv Strategic Partners, L. P. (10% Owner) | Sale | 1,119,000 | 22.00 | 24,618,000 |
| 2015-06-10 | Warden Charles M (Director) | Sale | 427,000 | 22.00 | 9,394,000 |
| 2015-05-13 | Sawhney Amarpreet (President and CEO) | Option Ex | 51,491 | 1.35 | 69,512 |
| 2015-02-27 | Lindstrom Richard L Md (Director) | Option Ex | 24,620 | .55 | 13,541 |
| 2015-02-02 | Polaris Venture Partners Special Founders' Fund V, L.p. (10% Owner) | Sale | 500,000 | 29.50 | 14,750,000 |
| 2014-07-30 | Ankerud Eric (See Remarks) | Buy | 1,000 | 13.00 | 13,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of OCUL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ocular Therapeutix, Inc (symbol OCUL, CIK number 1393434) see the Securities and Exchange Commission (SEC) website.